Synthesis, anticancer activity and pharmacokinetic analysis of 1-[(substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2012-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmc.2011.12.026PMID 22226981
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Predictive QSAR Model for hERG Inhibitors Using Bayesian and Random Forest Classification Method

  2011cited by this paper
• Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for anticancer agent.

  2011cited by this paper
• Extemporaneous Compounding of Oral Liquid Dosage Formulations and Alternative Drug Delivery Methods for Anticancer Drugs

  2011cited by this paper
• Lipid-based drug delivery systems for cancer treatment.

  2011cited by this paper
• The quinoxaline anti‐tumor agent (R+)XK469 inhibits neuroblastoma tumor growth

  2011cited by this paper
• Polymeric micelles for oral drug delivery.

  2010cited by this paper
• Oral Delivery of DMAB-Modified Docetaxel-Loaded PLGA-TPGS Nanoparticles for Cancer Chemotherapy

  2010cited by this paper
• Synthesis and anticancer activity of new 1-[(5 or 6-substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives.

  2010cited by this paper
• Design of Biodegradable Nanoparticles for Oral Delivery of Doxorubicin: In vivo Pharmacokinetics and Toxicity Studies in Rats

  2009cited by this paper
• A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.

  2008cited by this paper
• Oral lipid-based formulations.

  2007cited by this paper
• A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.

  2006cited by this paper
• Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs.

  2005cited by this paper
• Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate

  2004cited by this paper
• Pursuing the leadlikeness concept in pharmaceutical research.

  2004cited by this paper
• Anti-angiogenic and anti-tumor apoptotic activities of SJ-8002, a new piperazine derivative.

  2004cited by this paper
• Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships.

  2003cited by this paper
• DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS.

  2003cited by this paper
• Quinoxaline 1,4‐dioxides: Hypoxia‐selective therapeutic agents

  2002cited by this paper
• Molecular properties that influence the oral bioavailability of drug candidates.

  2002cited by this paper
• Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs.

  2001cited by this paper
• PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine.

  1998cited by this paper
• Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer

  1997cited by this paper
• New in vitro screening model for the discovery of antileukemic anticancer agents.

  1996cited by this paper
• Tyrosine kinase inhibition: an approach to drug development.

  1995cited by this paper
• Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. 2.

  1995cited by this paper
• Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.

  1994cited by this paper
• Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide.

  1992cited by this paper
• New colorimetric cytotoxicity assay for anticancer-drug screening.

  1990cited by this paper
• New approaches to antitumor drug screening: the human tumor colony-forming assay.

  1986cited by this paper
• Computer-Assisted Computation of Partition Coefficients from Molecular Structures Using Fragment Constants

  1979cited by this paper

• Synthesis, Anticancer Evaluation, and In Silico Docking Studies of 1-[(1-Phenyl-1H-1,2,3-triazol-5-yl)methyl]-4-(pyridin-2-yl)piperazine Hybrids as Potential MCF Antagonists

  2025cites this paper
• 1,4-Bis(2-Kloro-4-Nitrofenil)Piperazin Molekülünün Yapısının Aydınlatılması ve DNA ile Moleküler Kenetlenme Analizi

  2022cites this paper
• Synthesis and Vasorelaxant Evaluation of Novel 7-Methoxyl-2,3-disubstituted-quinoxaline Derivatives.

  2021cites this paper
• Benzopyrazine-Based Small Molecule Inhibitors As Trypanocidal and Leishmanicidal Agents: Green Synthesis, In Vitro, and In Silico Evaluations

  2021cites this paper
• 3‐(α‐Chlorobenzyl)quinoxalin‐2(1 H )‐ones as Versatile Reagents for the Synthesis of 3‐Benzylquinoxalin‐2(1 H )‐ones and Thiazolo[3,4‐ a ]quinoxalin‐4(5 H )‐ones

  2019cites this paper
• The Stability Study of a Novel Phenylpiperazine Derivative

  2019cites this paper
• An insight into medicinal chemistry of anticancer quinoxalines.

  2019cites this paper
• Regioselective addition of Grignard reagents to N-acylpyrazinium salts: synthesis of substituted 1,2-dihydropyrazines and Δ5-2-oxopiperazines

  2019cites this paper
• Luminescent bis(benzo[d]thiazolyl)quinoxaline: facile synthesis, nucleic acid and protein BSA interaction, live-cell imaging, biopharmaceutical research and cancer theranostic application

  2019cites this paper
• First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer

  2019cites this paper
• Chemical and CRISPR/Cas9 Tools for Functional Characterization of RNA Helicases

  2018cites this paper
• Synthesis of Quinoxalines

  2016cites this paper
• Quinoxaline Nucleus: A Promising Scaffold in Anti-cancer Drug Discovery.

  2016cites this paper
• A Novel Anti‐Cancer Agent, 1‐(3,5‐Dimethoxyphenyl)‐4‐[(6‐Fluoro‐2‐Methoxyquinoxalin‐3‐yl)Aminocarbonyl] Piperazine (RX‐5902), Interferes With β‐Catenin Function Through Y593 Phospho‐p68 RNA Helicase

  2015cites this paper
• Design, synthesis and biological evaluation of novel 1,2,4-triazolo and 1,2,4-triazino[4,3- a ]quinoxalines as potential anticancer and antimicrobial agents

  2015cites this paper
• SAR-studies on the importance of aromatic ring topologies in search for selective 5-HT(7) receptor ligands among phenylpiperazine hydantoin derivatives.

  2014cites this paper
• Recent advances in design of potential quinoxaline anti-infectives.

  2014cites this paper
• Present status of quinoxaline motifs: excellent pathfinders in therapeutic medicine.

  2014cites this paper
• Synthesis and cytotoxic properties of halogen and aryl-/heteroarylpiperazinyl derivatives of benzofurans.

  2014cites this paper
• Carbene‐Catalyzed Aroylation of a 2‐Chloroquinoxaline N‐Oxide with Aromatic Aldehydes at Room Temperature

  2014cites this paper
• An Efficient and Regioselective Synthesis of 2,3-Disubstituted 6-Aminoquinoxaline Derivatives Using Alkoxylation and Microwave-assisted Sonogashira Coupling

  2013cites this paper
• Efficient Synthesis of Quinoxaline Derivatives by Selective Modification of 3‐Chloro‐6‐fluoroquinoxalin‐2(1H)‐one 4‐Oxide

  2013cites this paper
• An evolving role of piperazine moieties in drug design and discovery.

  2013cites this paper
• A new ligustrazine derivative--pharmacokinetic evaluation and antitumor activity by suppression of NF-kappaB/p65 and COX-2 expression in S180 mice.

  2013cites this paper
• ScholarWorks @ UTRGV ScholarWorks @ UTRGV

  year unknowncites this paper